Le Lézard
Classified in: Health
Subjects: PDT, FVT

Fortune Launches New Advice Column with Founder, Investor, Entrepreneur Andy Dunn


"Ask Andy" features tips for launching a new business venture while maintaining a healthy mind

Bonobos and Pie co-founder, best-selling author of "Burn Rate," and mental health advocate shares personal insights on mental health struggles as a business founder

NEW YORK, April 30, 2024 /PRNewswire/ -- Fortune Media announced today the launch of Ask Andy, a recurring advice column for entrepreneurs, founders and startup executives, written by Andy Dunn, co-founder of e-commerce pioneer Bonobos and an investor in and advisor to other startups. Dunn's column features invaluable advice and insights on how to scale startups and handle the stress that comes with launching and leading a business.

Ask Andy answers readers' questions about founding a business, building the right team, raising capital, maintaining mental health, and more. Ask Andy is the first advice column from Fortune that takes a personalized look at how to balance a startup while maintaining a strong body and mind.

Dunn, business investor, mental health advocate and current CEO of IRL social network creator Pie, is the author of Burn Rate: Launching a Startup and Losing My Mind, a memoir on mental illness and entrepreneurship. The 2022 best-seller candidly explored his struggle with building a business from scratch while wrestling with undiagnosed bipolar disorder. He recently wrote for Fortune on knowing when to quit your startup and admit failure. Ask Andy can be found bi-weekly on Fortune.com.

"It's been exciting to field questions from all the great founders and builders out there," says Dunn. "They're raising great points about company culture, balancing work and family, and dealing with the challenges of creating a company. Startup life can be the greatest thing AND one of the hardest things: I've been there, and I am loving the discussion and am learning as much from their questions as they may be from my 'answers'."

"Andy has built a wealth of experience as a startup and VC, all while being keenly aware of the mental and physical toll entrepreneurs pay on their journeys," says Fortune editor-in-chief Alyson Shontell. "We are thrilled Fortune readers can tap into his wisdom, candor, and humor."

(Have a question for Ask Andy? Send it to him here.)

Dunn will also be a co-chair of Fortune Brainstorm Tech 2024 Summit, July 15-17 in Park City, Utah, where he'll guide industry-leading conversations and bring Ask Andy live to the conference stage.

About Fortune
Fortune's mission is to change the world by making business better. We achieve that by providing trusted information, telling great stories, and building world-class communities. We measure performance by rigorous benchmarks, and we hold companies accountable. Our goal is to make Fortune a force for good through its second century and beyond. For more information, visit fortune.com.

Media Contacts:
Patrick Reilly
Fortune
[email protected]

Amy Galleazzi
[email protected]

SOURCE FORTUNE Media


These press releases may also interest you

at 18:54
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...

at 18:12
Functional Food Ingredients Market size is set to grow by USD 53.14 bn from 2024-2028, increased demand for functional food ingredients from probiotics segment to boost the market growth, Technavio
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

More news about Health...


News published on and distributed by: